Impact of Peptide Receptor Radionuclide Therapy using Y-90 DOTA-TATE/Lu-177 DOTA-TATE on renal tubular function: Long term follow-up

被引：0
|
作者：
Prasad, V.
Baum, R. P.
机构：
[1] Zent Klin Bad Berka GmbH, Dept Nucl Med, Bad Berka, Germany
[2] Zent Klin Bad Berka GmbH, Ctr PET CT, Bad Berka, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2008年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S351 / S351
页数：1
相关论文
共 50 条
  • [31] 177Lu-DOTA-TATE in Peptide Receptor Radionuclide Therapy: first year experience in Turkey
    Kabasakal, L.
    Demirci, E.
    Ocak, M.
    Decristoforo, C.
    Papilla, C.
    Araman, A.
    Uslu, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S428 - S428
  • [32] Induction and Maintenance Regimen with Peptide Receptor Radionuclide Therapy (PRRT) Lu-177-DOTA-TATE (Lu-177) in Patients with Advanced Neuroendocrine Tumours (NET)
    Mc Ewan, A.
    Wieler, M.
    Makis, W.
    McMullen, T.
    Morrish, D.
    MacLeod, S.
    Schrader, L.
    Sawyer, M.
    NEUROENDOCRINOLOGY, 2016, 103 : 94 - 94
  • [33] Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours
    Geenen, Lorain
    Nonnekens, Julie
    Konijnenberg, Mark
    Baatout, Sarah
    De Jong, Marion
    Aerts, An
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 102 : 1 - 11
  • [34] Overall survival (OS) and progression-free survival (PFS) in patients with advanced, non-resectable, progressive rectal NET treated with 90Y DOTA-TATE, 177Lu DOTA-TATE and mix of both as systemic radioligand therapy: Real-world data
    Cwikla, J. B.
    Kolasinska-Cwikla, A. D.
    Sankowski, A.
    Palucki, J.
    Roszkowska-Purska, K.
    Chrapowicki, E.
    Ostrowski, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S760 - S760
  • [35] Toxicity of Peptide Receptor Radiotherapy (PRRT) Using the Somatostatin Analogue DOTA-NOC Labelled with Y-90 or Lu-177
    Junak, D. Handkiewicz
    Baum, R. P.
    Jarzak, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S202 - S202
  • [36] Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment (vol 66, pg 269, 2022)
    Mottaghi, Mahdi
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2022, 66 (04): : 587 - 587
  • [37] Combined octreotide and peptide receptor radionuclide therapy (90Y-DOTA-TATE) in case of malignant insulinoma
    Fischbach, Jakub
    Gut, Pawel
    Matysiak-Grzes, Magdalena
    Klimowicz, Aleksandra
    Gryczynska, Maria
    Wasko, Ryszard
    Ruchala, Marek
    NEUROENDOCRINOLOGY LETTERS, 2012, 33 (03) : 273 - 278
  • [38] Effectivity of a combined treatment with the m-TOR inhibitor RAD001 and Peptide Receptor Radionuclide therapy with Lu-177 DOTA TATE evaluated with Ga-68 DOTA TATE PET in a tumor model of the mouse
    Zellmer, J.
    Vomacka, L.
    Boening, G.
    Gildehaus, F. J.
    Carlsen, J.
    Mille, E.
    Hacker, M.
    Bartenstein, P.
    Haug, A. R.
    Ilhan, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S229 - S229
  • [39] Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors
    Jiang, Yuanyuan
    Liu, Qingxing
    Wang, Guochang
    Sui, Huimin
    Wang, Rongxi
    Wang, Jiarou
    Zhang, Jingjing
    Zhu, Zhaohui
    Chen, Xiaoyuan
    THERANOSTICS, 2022, 12 (15): : 6437 - 6445
  • [40] Side-effects and response to the radioisotope 90Y/177Lu DOTA-TATE therapy in patients with disseminated NET - Do repeated cycles of PRRT increase toxicity of the therapy?
    Sowa-Staszczak, Anna
    Hubalewska-Dydejczyk, Alicja B.
    Stefanska, Agnieszka
    Kunikowska, Jolanta
    Krolicki, Leszek
    Pach, Dorota
    Mikolajczak, Renata
    Pawlak, Dariusz
    Trofimiuk, Malgorzata
    ENDOCRINE JOURNAL, 2010, 57 : S587 - S587
12345